BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Athersys receives U.S. Patent covering adult stem cell composition & production
News | 02. 10. 2010
Athersys
CLEVELAND, Feb. 10, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has been granted U.S. patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions. Athersys also announced that it has been granted -- and the opposition period has cleared -- EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation, expansion, and usage.
